Article summary
Law360, London: Samsung Bioepis has fought back against an application by Alexion to prevent it from selling a biosimilar version of a patented blood treatment drug by a rival, telling a court that this will not infringe the protections of an AstraZeneca subsidiary over the medicine.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial